Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Tucci

Showing results (121-130 of 154) with videos related to

Pageof 16
Sort By:
Hematological Oncology|September 30, 2022
The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana LinfomiEmanuele Cencini, Alessandra Tucci, Benedetta Puccini, et al.
Hemasphere|August 18, 2025
Autologous stem cell transplantation in NK/T-cell lymphoma: Prognostic impact of EBV-DNA in a multinational cohort-A study by the EBMT Lymphoma Working PartyPhilipp Berning, Maud Ngoya, Won Seog Kim, et al.
Hematological Oncology|July 17, 2010
Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcomeEkaterina Chigrinova, Michael Mian, Marta Scandurra, et al.
Leukemia & Lymphoma|April 5, 2018
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana LinfomiFrancesco Zaja, Flavia Salvi, Maura Rossi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trialSara Galimberti, Stefano Luminari, Elena Ciabatti, et al.
Haematologica|November 17, 2022
Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL)Alessandra Tucci, Francesco Merli, Alberto Fabbri, et al.
Blood Advances|January 5, 2024
IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphomaAnnarita Conconi, Annalisa Chiappella, Andrés J M Ferreri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2017
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab MonotherapyEmanuele Zucca, Annarita Conconi, Giovanni Martinelli, et al.
Lancet (London, England)|December 10, 2025
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trialLorenzo Falchi, Marcel Nijland, Huiqiang Huang, et al.
Hematological Oncology|May 13, 2025
Comparative Effectiveness of R-miniCOMP Versus R-miniCHOP in Older Non-Fit Patients With Diffuse Large B-Cell Lymphoma: Insights From a "Fondazione Italiana Linfomi" Cohort StudyAlberto Bavieri, Sara Veronica Usai, Michele Merli, et al.
Pageof 16

Showing results (121-130 of 154) with videos related to

Sort By:
Pageof 16
Hematological Oncology|September 30, 2022
The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana LinfomiEmanuele Cencini, Alessandra Tucci, Benedetta Puccini, et al.
Hemasphere|August 18, 2025
Autologous stem cell transplantation in NK/T-cell lymphoma: Prognostic impact of EBV-DNA in a multinational cohort-A study by the EBMT Lymphoma Working PartyPhilipp Berning, Maud Ngoya, Won Seog Kim, et al.
Hematological Oncology|July 17, 2010
Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcomeEkaterina Chigrinova, Michael Mian, Marta Scandurra, et al.
Leukemia & Lymphoma|April 5, 2018
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana LinfomiFrancesco Zaja, Flavia Salvi, Maura Rossi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trialSara Galimberti, Stefano Luminari, Elena Ciabatti, et al.
Haematologica|November 17, 2022
Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL)Alessandra Tucci, Francesco Merli, Alberto Fabbri, et al.
Blood Advances|January 5, 2024
IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphomaAnnarita Conconi, Annalisa Chiappella, Andrés J M Ferreri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2017
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab MonotherapyEmanuele Zucca, Annarita Conconi, Giovanni Martinelli, et al.
Lancet (London, England)|December 10, 2025
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trialLorenzo Falchi, Marcel Nijland, Huiqiang Huang, et al.
Hematological Oncology|May 13, 2025
Comparative Effectiveness of R-miniCOMP Versus R-miniCHOP in Older Non-Fit Patients With Diffuse Large B-Cell Lymphoma: Insights From a "Fondazione Italiana Linfomi" Cohort StudyAlberto Bavieri, Sara Veronica Usai, Michele Merli, et al.
Pageof 16